Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)

Ori Toker1, Philip J Hashkes21Department of Pediatrics, Shaare Zedek Medical Center, affiliated with the Hadassah-Hebrew University Medical School, Jerusalem, Israel; 2Pediatric Rheumatology Unit, Shaare Zedek Medical Center, Jerusalem, Israel, Cleveland Clinic Lerner Medical School, Case Western Re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ori Toker, Philip J Hashkes
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/fe1ae3d55eaf4938abed63abd177aab2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fe1ae3d55eaf4938abed63abd177aab2
record_format	dspace
spelling	oai:doaj.org-article:fe1ae3d55eaf4938abed63abd177aab22021-12-02T01:42:30ZCritical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)1177-54751177-5491https://doaj.org/article/fe1ae3d55eaf4938abed63abd177aab22010-05-01T00:00:00Zhttp://www.dovepress.com/critical-appraisal-of-canakinumab-in-the-treatment-of-adults-and-child-a4445https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Ori Toker1, Philip J Hashkes21Department of Pediatrics, Shaare Zedek Medical Center, affiliated with the Hadassah-Hebrew University Medical School, Jerusalem, Israel; 2Pediatric Rheumatology Unit, Shaare Zedek Medical Center, Jerusalem, Israel, Cleveland Clinic Lerner Medical School, Case Western Reserve University, Cleveland, OH, USAAbstract: The cryopyrin-associated syndromes (CAPS) include three autosomal-dominant syndromes, that are caused by a mutation in the NLRP3 gene on chromosome 1, encoding the cryopyrin protein. These syndromes, familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal-onset multisystem inflammatory disease, are characterized by urticaria-like rash, fever, central nervous system inflammation, an arthropathy and a risk of the development of amyloidosis in a respectively escalating degree of severity between the various syndromes. Recently the role of cryopyrin in the regulation of interleukin (IL)-1 production and activation was described and anti IL-1 therapies were found to be very effective in treating these syndromes. There are several types of anti IL-1 medications based on different mechanisms of antagonizing IL-1. This paper focuses on the efficacy and safety of canakinumab, a long-acting humanized anti IL-1 antibody, in treating these syndromes.Keywords: canakinumab, cryopyrin-associated periodic syndromes, biologics, treatment, autoinflammatory diseases Ori TokerPhilip J HashkesDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2010, Iss default, Pp 131-138 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Ori Toker Philip J Hashkes Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
description	Ori Toker1, Philip J Hashkes21Department of Pediatrics, Shaare Zedek Medical Center, affiliated with the Hadassah-Hebrew University Medical School, Jerusalem, Israel; 2Pediatric Rheumatology Unit, Shaare Zedek Medical Center, Jerusalem, Israel, Cleveland Clinic Lerner Medical School, Case Western Reserve University, Cleveland, OH, USAAbstract: The cryopyrin-associated syndromes (CAPS) include three autosomal-dominant syndromes, that are caused by a mutation in the NLRP3 gene on chromosome 1, encoding the cryopyrin protein. These syndromes, familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal-onset multisystem inflammatory disease, are characterized by urticaria-like rash, fever, central nervous system inflammation, an arthropathy and a risk of the development of amyloidosis in a respectively escalating degree of severity between the various syndromes. Recently the role of cryopyrin in the regulation of interleukin (IL)-1 production and activation was described and anti IL-1 therapies were found to be very effective in treating these syndromes. There are several types of anti IL-1 medications based on different mechanisms of antagonizing IL-1. This paper focuses on the efficacy and safety of canakinumab, a long-acting humanized anti IL-1 antibody, in treating these syndromes.Keywords: canakinumab, cryopyrin-associated periodic syndromes, biologics, treatment, autoinflammatory diseases
format	article
author	Ori Toker Philip J Hashkes
author_facet	Ori Toker Philip J Hashkes
author_sort	Ori Toker
title	Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
title_short	Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
title_full	Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
title_fullStr	Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
title_full_unstemmed	Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
title_sort	critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (caps)
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/fe1ae3d55eaf4938abed63abd177aab2
work_keys_str_mv	AT oritoker criticalappraisalofcanakinumabinthetreatmentofadultsandchildrenwithcryopyrinassociatedperiodicsyndromecaps AT philipjhashkes criticalappraisalofcanakinumabinthetreatmentofadultsandchildrenwithcryopyrinassociatedperiodicsyndromecaps
_version_	1718402935953555456

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)

Ejemplares similares